High Accuracy of PSMA PET in Initial Staging of High-Risk Prostate Cancer

Comment

Joseph Waller et al. Radiol Imaging Cancer. 2020.

. 2020 Jul 31;2(4):e204025.

doi: 10.1148/rycan.2020204025. eCollection 2020 Jul.

No abstract available

Comment on

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Hofman MS, et al. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22. Lancet. 2020. PMID: 32209449 Clinical Trial.

1. Hofman MS, Lawrentschuk N, Francis RJ, et al. . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395(10231):1208–1216. 10.1016/S0140-6736(20)30314-7 - DOI - PubMed